Claim OwnershipTreating Together
Subscribed: 7Played: 173
Subscribe
© MJH LifeSciences
Description
Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.
74 Episodes
Reverse
Benjamin Garmezy, MD, and Alexander Kenigsberg, MD, discuss strategies for preserving organs in GU cancers in the Treating Together podcast.
Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians.
In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.
In this episode of Emerging Experts, Xiaojie Zhang, MD, a hematology/oncology fellow, and Akshat Singhal, PhD, a postdoctoral scholar, both at UC San Diego, shed light on innovative research leveraging deep learning to predict how patients with ER-positive/HER2-negative (ER+/HER2-) breast cancer will respond to palbociclib (Ibrance), a common first-line treatment for this patient population. Their work, fueled by the desire to improve precision oncology, demonstrates the significant potential of artificial intelligence (AI) in guiding cancer care.
In this episode of Targeted Talks, Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.
David A. Russler-Germain, MD, PhD, physician-scientist at Washington University School of Medicine and Siteman Cancer Center, discusses his path in oncology and the many advancements shaping lymphoma treatment today.
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan for the treatment of patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy.
In this episode of Targeted Talks, Sanjay K. Juneja, MD, hematologist & medical oncologist at Mary Bird Perkins Cancer Center, discusses the exciting advancements of artificial intelligence in 2024, specifically focusing on its transformative impact on early cancer detection.
In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, executive medical director of oncology services at St. Elizabeth Healthcare, discusses the transformative impact of artificial intelligence in oncology.
In this episode of Targeted Talks, Seth Wander, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor at Harvard Medical School, discusses the clinical importance of ESR1 mutations in hormone receptor-positive metastatic breast cancer and how these mutations influence treatment approaches.
Antonious Hazim, MD, hematology medical oncology fellow at Mayo Clinic, Rochester, Minnesota, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.
In this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio and the leader of the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discusses the background, findings, and implications of the phase 3 EMERALD trial.
In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.
In this episode of Emerging Experts, Paolo Tarantino, MD, researcher at the European Institute of Oncology, and clinical research fellow at Dana-Farber Cancer Institute, discusses the latest developments in breast cancer research and treatment, focusing on the evolving understanding of HER2-low breast cancer subtypes and the potential advantages of using antibody-drug conjugates.
In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.
In this episode of Emerging Experts, Yu Fujiwara, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.
In this episode of Targeted Talks, Nini Wu, MD, MBA, chief medical and development officer at Cardinal Health, shares her insights on the ever-changing world of technology in the community oncology setting.
Comments
Download from Google Play
Download from App Store
United States